Qing Li

Qing Li

Auto-generated profile, based on publicly available information

Qing Li

National Key Laboratory of Veterinary Public Health Security, Beijing Key Laboratory of Detection Technology for Animal-Derived Food, College of Veterinary Medicine, China Agricultural University, 100193 Beijing, People's Republic of China

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2020 in ACS Chemical Biology
Verified
Journal Article
Closed access
QLQing Li
Qing Li
CCChingshen Chan
Chingshen Chan
NPNorman Peterson
Norman Peterson
RHRichard N. Hanna
Richard N. Hanna
AAAlex Alfaro
Alex Alfaro
JSJose Luis Santos
Jose Luis Santos

28 January 2016 in Cancer Biology & Therapy
Verified
Journal Article
Open access
BDBin Dong
Bin Dong
CZChanghua Zhou
Changhua Zhou
PHPing He
Ping He
JLJing Li
Jing Li
SCSiqi Chen
Siqi Chen
ZWzhong wang
zhong wang
One of the most active fields in cancer immunotherapy is the study of bispecific antibodies, which engage immune cells to kill cancer cells. However, a variety of issues are associated with most of current bispecific antibody formats. In this study, we present a novel bispecific antibody, BiSS (Bispecific antibody with Single domain, Single domain antibodies), which was constructed by linking 2 single domain antibodies, anti-CEA and anti-CD16, in tandem. Unlike most other bispecific antibodies, the BiSS antibody can be expressed and purified from E.coli in large quantities. By recruiting natural killer cells (NK cells) to CEA-positive cancer cells, BiSS led to cancer cell death in vitro. In xenograft models, the BiSS protein blocked cancer progression. The data suggested that the single domain-based bispecific antibody BiSS was functional and can be potentially applied to a broad range of immunotherapies.

29 September 2019 in Cancer Biology & Therapy
Verified
Journal Article
Open access
YZYining Zhao
Yining Zhao
YLYumei Li
Yumei Li
XWXiaoqiong Wu
Xiaoqiong Wu
LLLi Li
Li Li
JLJiayu Liu
Jiayu Liu
ZWZhong Wang
Zhong Wang
CD16a (FcγRIIIa) mediates the antibody dependent cellular cytotoxicity (ADCC) and is important for anti-tumor activities of many therapeutic antibodies. Bispecific antibody targeting natural killer (NK) cells has been studied for cancer therapy. In this work, anti-CD16a single-domain antibodies were identified from hCD16a immunized camel. Bispecific antibodies are then constructed by fusing these single domain antibodies with an anti-CEA single domain antibody. These bispecific antibodies can recruite NK cells to kill CEA-positive tumor cells, and inhibit tumor growth in vivo, suggesting that these anti-CD16a single domain antibodies are powerful tools to engaging NK cells for cancer therapy.

1 June 2018 in Journal of Controlled Release
Verified
Journal Article
Closed access
QLQing Li
Qing Li
JWJason B. White
Jason B. White
NPNorman C. Peterson
Norman C. Peterson
KRKeith W. Rickert
Keith W. Rickert
CLChristopher O. Lloyd
Christopher O. Lloyd
PTPing Tsui
Ping Tsui

26 March 2019 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
QLQing Li
Qing Li
ABAllison Barrett
Allison Barrett
BVBalakumar Vijayakrishnan
Balakumar Vijayakrishnan
ATArnaud Tiberghien
Arnaud Tiberghien
RBRhiannon Beard
Rhiannon Beard
MBM. Jack Borrok
M. Jack Borrok

5 April 2023 in Biotechnology Advances
Verified
Journal Article
Closed access
YZYingjie Zhang
Yingjie Zhang
QLQing Li
Qing Li
LLliang luo
liang luo
CDChangfei Duan
Changfei Duan
JSJianzhong Shen
Jianzhong Shen
Zhanhui WangZhanhui Wang
Zhanhui Wang